Dynorphin A

O=C([C@H]1N(CCC1)C([C@H](CCCNC(N)=N)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@@H](NC(CNC(CNC([C@@H](N)CC2=CC=C(C=C2)O)=O)=O)=O)CC3=CC=CC=C3)=O)=O)=O)=O)=O)=O)N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@H](C(O)=O)CCC(N)=O)=O)=O)=O)CC4=CNC5=CC=CC=C45)=O)=O)=O

[1]Zhang, et al.Dynorphin A as a Potential Endogenous Ligand for Four Members of the Opioid Receptor Gene Family. J Pharmacol Exp Ther. 1998 Jul;286 (1) :136-41.|[2]Aruna Sharma, et al. Monoclonal antibodies as novel neurotherapeutic agents in CNS injury and repair. Int Rev Neurobiol. 2012;102:23-45. |[3]I. N. SINGH, et al. Dynorphin A (1–17) induces apoptosis in striatal neurons in vitro through AMPA/kainate receptor-mediated cytochrome c release and caspase-3 activation. Neuroscience. 2003;122 (4) :1013-23. |[4]K F Hauser, et al. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol. 1999 Dec;160 (2) :361-75. |[5]B J Van de Heijning, et al. Dynorphin-A and vasopressin release in the rat: a structure-activity study. Neuropeptides. 1994 Jun;26 (6) :371-8. |[6]Takayoshi Mamiya, et al. Dynorphin a (1-13) alleviated stress-induced behavioral impairments in mice. Biol Pharm Bull. 2014;37 (8) :1269-73.